Can the level of HbA1C predict diabetic retinopathy among type II diabetic patients?

Javad Setareh, Ghazale Hoseinzade, Batoul Khoundabi, Mahsa Kamali, Ata Ebrahim, Andarz Fazlollahpour-Naghibi, Mohammad Zareei, Mona Mohamaditabar and Ali Makaremi

Abstract

Background: Hemoglobin A1C (HbA1C) test is the best care evaluation measurement due to a strong correlation between the test results and diabetic complications. So, this cross-sectional study aimed to assess whether the level of HbA1C can predict Diabetic Retinopathy (DR) among Type 2 diabetes mellitus (T2DM) in the Iranian population.

Method: One hundred sixty-eight diabetic patients were selected via the convenience sampling method. Data were collected by research made questionnaire scale and laboratory test had been done. To estimate the cut off point for some variables statistical tests, formal measures of classification performance, model evaluation criteria and a decision Tree were used.

Results: The prevalence of DR was 29.8%. The Receiver Operating Characteristic (ROC) curve and decision tree showed the optimal cut-off point for the HbA1C variable that separates the patient with and without DR is HbA1C = 8.15.

Conclusion: Current study showed an appropriate cutoff point for detecting the development of DR among diabetic patients. So, this cutoff point can be used as guide evidence in several clinical judgments on the Iranian population.

Keywords: Diabetes, Retinopathy, HbA1C, Epidemiology, Diagnosis

Background

Type 2 Diabetes Mellitus (T2DM) is defined as relative insulin deficiency secondary to pancreatic β-cell dysfunction and also insulin resistance in specific organs [1]. The overall increasing trend has been predicted in diabetic prevalence so that will increase from 415 million patients in 2015 to 642 million patients in 2040 all over the world [2]. Another report showed the prevalence of diabetic patients increased by 69% in developing countries from 2010 to 2030 [3]. Based on a World Health Organization (WHO) report in 2016, the prevalence of type 2 diabetes in Iran was 10.3% [4] and the Iranian population pays vast sums for the treatment of diabetes-related health complications [1]. The complications of diabetes mellitus are divided to macro vascular complications such as cardiovascular disease with 50% prevalence and micro vascular complications related to the kidney, the retina and the nervous system, which involved 27% of T2DM patients [5]. Diabetic Retinopathy (DR) is one of the major micro vascular complications of the diabetic disease and also divided into two stages, including Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR) that occur in the early stage and advanced stage of DR, respectively [6]. Diabetic Macular Edema (DME) has been recognized as swelling and thickening of the macula and is the most prevalent cause of blindness among DR patients [7]. A retrospective cohort study revealed eyes with moderate NPDR, severe NPDR, and PDR were more likely to develop sustained
blindness after 2 years of DR diagnosis versus others [8]. Hence assessing these complications is important. The development of DR is a multiplex and multidimensional process, so the diagnosis of DR is challenging [9, 10]. A systematic review in Iran showed the prevalence of DR, NPDR and PDR were 41.9, 32.2 and 13.2%, respectively [11]. Another systematic review revealed NPDR is more common among Asian DR patients so screening management is crucial [12]. Nevertheless, 45.8% of all diabetic patients were undiagnosed and so untreated. It causes diabetic patients at higher risk of developing complications [13, 14]. Hence, early detection of T2DM is the main factor for optimal outcomes by preventing or delaying the development of complications [15]. World Health Organization (WHO) reported some cost effective interventions that can enhance diabetic patient outcomes such as regular screening for damage to the eyes [16]. Glycated hemoglobin (HbA1c) reflects the chronic blood glucose concentration and it is used as an index to reflect the average blood glucose levels of the past 1–2 months [17]. HbA1c test is the best care evaluation measurement due to a strong correlation between the test results and the diabetic complications [18]. A study revealed when HbA1c was ≥ 6.8%, the odds ratio for diabetic retinopathy increased significantly [17]. Another study showed the cut off 6.6% is the best detected for the presence of any DR [19]. Sumner et al. believed that various risk factors could affect the results of HbA1c [20].

Given the importance of screening DR among T2DM to reduce complications and enhance the quality of life, using the diagnostic criteria may be essential to help health care providers. Also, the relationship between HbA1C and DR is race dependent [17]. However, among the Iranian population this cutoff point is unclear. So, the purpose of this cross-sectional study was to assess whether the level of HbA1C can predict DR among T2DM in the Iranian population.

**Methods**

**Study design and setting**

This cross-sectional study was conducted on Type 2 diabetes mellitus (T2DM) patients where referred to the outpatient clinic between March 2019 and February 2020 in Mazandaran province, Iran. The outpatient clinic is affiliated to one of the teaching hospitals in the north of Iran, and people could refer to this clinic for treatment. Among these people, those were under the DM treatment selected.

**Sample and sampling method**

Participants were selected via the convenience sampling method, and the sample size was calculated 147 patients following the results obtained by Yao et al. study [21], considering \( \alpha = 0.05 \) and error equal to 0.07 (Fig. 1). Patients who had informed consent to participate, aged at least 18 years old, known treated diabetes disease at least 1 year and had the ability to communicate were included. Type I diabetes patients, pregnant women and subjects missing Fasting Plasma Glucose (FPG), HbA1c or fundus photography were excluded. In this study Diabetes was defined as self-reported of a previous diagnosis of the disease, use of diabetic medications, or HbA1c 6.5% or greater.

**Measurements instrument**

Data were collected by three parts questionnaire. The first part was a researcher-made socio-demographic questionnaire including family history, medical history, age, gender, etc. One of the researchers completed this part via face-to-face interviews. The second part included physical examination such as measurement of height, weight and waist circumference performed by one of the researchers. In this part also, laboratory tests consisted of FPG, HbA1c, Cholesterol (Chol), Triglyceride (TG), High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), Blood Urea Nitrogen (BUN), Creatinine [1], etc. had been done after a minimum overnight fasting of 12 hours. FPG and HbA1c were determined by the chromatography method.

**Data collection**

After completing these two-section, one of the researchers made a telephone call to all the T2DM patients to make an appointment for a clinical visit in the ophthalmology clinic in the same hospital. On the second visit, the third part of the questionnaire was completed. During this visit, Best Corrected Visual Acuity (BCVA), by slit lamp bio microscopy and Optical Coherence Tomography (OCT) were performed for both eyes by a specialist. Also, Fundus photographs (FP) were taken to evaluate of the presence and signs of DR and Diabetes Macular Edema (DME).

In the ophthalmology visits after pupil dilatation with 1.0% tropicamide and 10% phenylephrine, fundus photographs (45° color digital images of the retina) were taken from both eyes of each participant by a technologist using a Topcon TRC-NW7SF fundus camera (Topcon corporation, Tokyo, Japan). The first image was centered on the macula, whereas the second one was centered on
the optic nerve. The photographs were assessed according to the international clinical DR severity scale [22] by photographic graders blinded to the clinical information of the participants. In the present study the kappa coefficient between two graders was 0.89. This scale rates DR at five different levels: (i) no retinopathic changes (Equivalent to the early Treatment of Diabetic Retinopathy Study (ETDRS); scale level 10); (ii) mild Non-Proliferative Diabetes Retinopathy (NPDR); equivalent to ETDRS level 20; (iii) moderate NPDR (equivalent to ETDRS levels 35, 43, and 47); (iv) severe NPDR (equivalent to ETDRS levels 53A-53E); and (v) Proliferative Diabetes Retinopathy (PDR) (equivalent to ETDRS levels 61 or higher). As mentioned previously, the presence of DR was defined as the presence of moderate (level iii) or severe non-proliferative (level iv) DR, or proliferative (level v) DR in each eye.

**Data analysis**

Finally, the patients were divided into two groups (with DR and without DR). Then a comparison between them was made in terms of variables. The data were analyzed using the statistical package IBM SPSS version 24.0 (Statistical Package for the Social Sciences, Chicago, IL). Kolmogorov-Smirnov test was applied to test the normality distribution for quantitative variables. To explore the independent nature of some categorical variables, chi-square or exact Fisher tests were used. The comparison of the means between two groups was done by independent t-test for age and Mann-Whitney test for the rest of the variables.

**Table 1** Socio-demographic characteristics of T2DM patients

| Variables                | Patients (n = 168) |
|--------------------------|-------------------|
| Gender                   |                   |
| Male                     | 53 (31.5%)        |
| Female                   | 115 (68.5%)       |
| DR                       |                   |
| Yes                      | 50 (29.8%)        |
| No                       | 118 (70.2%)       |
| Severity of DR (OS)      |                   |
| Mild NPDR                | 11 (22.0%)        |
| Moderate NPDR            | 20 (40.0%)        |
| Severe NPDR              | 12 (24.0%)        |
| PDR                      | 7 (14.0%)         |
| Severity of DR (OD)      |                   |
| Mild NPDR                | 13 (26.0%)        |
| Moderate NPDR            | 18 (36.0%)        |
| Severe NPDR              | 12 (24.0%)        |
| PDR                      | 7 (14.0%)         |
| Age (year)               | 56.01 ± 10.79     |
| Duration of DM (year)    | 11.61 ± 7.58      |

**Table 2** Comparison demographic variables, micro-vascular, macro-vascular complications and refractive errors among patients with and without DR

| Variable          | With DR n = 50 | Without DR n = 118 | p-value |
|-------------------|----------------|-------------------|---------|
| Gender            |                |                   |         |
| Male              | 12 (24.0%)     | 41 (37.4%)        | 0.205*  |
| Female            | 10 (20.8%)     | 13 (11.0%)        | 0.082*  |
| Age, (Year)       | 59.6 ± 10.79   | 56.01 ± 10.79     |         |
| BMI (Kg/m²)       | 28.2 ± 6.1     | 29.5 ± 4.0        | 0.108** |
| YOA               | 14.0 ± 7.8     | 10.7 ± 7.4        | 0.006** |
| HbA1C             | 8.5 ± 1.8      | 7.8 ± 1.6         | 0.007** |
| FBS               | 166.0 ± 56.8   | 165.1 ± 61.4      | 0.718***|
| BS                | 250.0 ± 97.3   | 231.1 ± 100.3     | 0.311***|
| BUN               | 23.4 ± 10.7    | 20.6 ± 10.3       | 0.056** |
| Cr                | 1.1 ± 0.4      | 1.6 ± 0.5         | 0.064***|
| HDL               | 44.7 ± 11.4    | 44.0 ± 12.8       | 0.498** |
| LDL               | 84.6 ± 26.4    | 88.1 ± 40.2       | 0.936***|
| TG                | 170.5 ± 90.3   | 183.8 ± 115.3     | 0.661***|
| Chol              | 165.4 ± 67.2   | 172.7 ± 59.8      | 0.369***|
| VAR               | 6.2 ± 2.9      | 7.2 ± 2.8         | 0.024***|
| VAL               | 60 ± 2.9       | 7.3 ± 2.6         | 0.002***|
| HTN               | 29 (58.0%)     | 65 (55.1%)        | 0.738*  |
| Thyroid Disease   |                |                   |         |
| Hypothyroidism    | 13 (26.0%)     | 12 (10.2)         | 0.22*   |
| Normal            | 37 (74.0%)     | 103 (87.3%)       |         |
| Hyperthyroidism   | 0 (0.0%)       | 3 (2.5)           |         |
| Gl                | 30 (60.0%)     | 33 (44.9)         | 0.092*  |
| ME                | 11 (22.0%)     | 4 (3.4)           | <0.001* |
| PR                | 7 (14.0%)      | 12 (10.2)         | 0.474*  |
| Cat               | 27 (54.0%)     | 41 (34.7)         | 0.025** |
| P                 | 14 (28.0%)     | 5 (4.2)           | <0.001* |
| IOP L             | 4.3 ± 3.6      | 4.8 ± 3.7         | 0.671***|
| IOP R             | 4.2 ± 3.6      | 4.8 ± 3.6         | 0.642** |

Categorical and quantitative items have been shown by n (%) and Mean ± SD respectively

**BMl Body Mass Index, HbA1C Hemoglobin A1C, FBS Fasting Blood Sugar, BS Blood Sugar, BUN Blood Urea Nitrogen, Cr Creatinine, HDL High-Density Lipoprotein, LDL Low-Density Lipoprotein, TG Triglyceride, Chol Cholesterol, IOP Intra Ocular Pressure, R Right, L Left, Cat Cataract, ME Macular Edema, HTN Hypertension, YOA Years of Affiliations, VAR Visual Acuity Right, VAL Visual Acuity Left, GI Gastrointestinal, P Pterygium, SD Standard Deviation

*Chi-square **T-test ***Mann-whitney
method, was used to estimate the cut off points for some studied variables. It uses the Classification and Regression Tree according to the specific variables used (Continuous and Categorical) by Classification and Regression Tree (CART) and Chi-squared Automatic Interaction Detection (CHAID).

Statistical significance mainly depends on the sample size, the data’s quality and statistical procedures’ power. Then, we used the effect sizes to describe the strength of a phenomenon. The most popular effect size measure surely is Cohen’s d (Cohen, 1988) used in this research.

Results
Socio-demographic characteristics of T2DM patients
Of a total of 327 diabetes patients, 168 participants were assessed and received eyes examination. The results revealed most of the patients were female (68.5%) and mean ± SD age and duration of DM were 56.01 ± 10.79 and 11.61 ± 7.58 years, respectively. The prevalence of DR was 29.8%. Most of the participants had moderate NPDR with the prevalence of 40.0 and 36.0% in OS and OD, respectively (Table 1).

Comparison of demographic variables and complications stratified by DR and severity of DR
Patients with and without DR differed significantly in terms of age, Years of Affiliations (YOA), HbA1C, Visual Acuity Right (VAR), Visual Acuity Left (VAL), thyroid disease and the history of cataract and pterygium (P<0.05; Table 2). But the severity of DR differed significantly in terms of HbA1C, history of GI disease and pterygium (P<0.05; Table 3).

Optimal cut-off point for the HbA1C variable in T2DM
ROC curve and decision tree (Figs 2 and 3) showed the optimal cut-off point for the HbA1C

Table 3 Comparison of demographic variables, micro ‑vascular and macro ‑vascular complications in patients with DR stratified by severity of disease

| Items                              | Mild NPDR | Moderate NPDR | Severe NPDR | PDR | p-value |
|------------------------------------|-----------|---------------|-------------|-----|---------|
| Gender                             | n = 14    | n = 18        | n = 12      | n = 6 |        |
| Gender                             | 5(35.7)   | 5(27.8)       | 1(8.3)      | 1(16.7) | 0.328*  |
| Insulin                            | 2(14.2)   | 4(22.2)       | 2(16.7)     | 2(33.3) | 0.882*  |
| Age                                | 60.7 ± 6.6| 59.9 ± 7.0    | 59.0 ± 6.0  | 59.5 ± 4.1 | 0.899** |
| BMI (Kg/m²)                        | 27.7 ± 8.7| 28.8 ± 5.0    | 29.2 ± 3.9  | 26.8 ± 4.8 | 0.827** |
| YOA                                | 15.4 ± 8.0| 12.4 ± 6.7    | 15.8 ± 8.2  | 13.3 ± 10.5 | 0.498***|
| HbA1C                              | 8.9 ± 1.3 | 8.0 ± 1.2     | 9.2 ± 1.4   | 7.8 ± 1.6  | 0.029*  |
| FBS                                | 165.2 ± 75.1| 154.6 ± 41.9 | 132.5 ± 59.7 | 151.8 ± 54.6 | 0.583***|
| BS                                 | 296.3 ± 117.7| 218.7 ± 78.1 | 247.7 ± 90.2 | 240.5 ± 108.5 | 0.204***|
| BUN                                | 26.0 ± 14.0| 23.4 ± 9.7    | 21.8 ± 9.6  | 22.7 ± 11.0 | 0.894***|
| Cr                                 | 1.0 ± 0.2 | 1.1 ± 0.4     | 1.0 ± 0.3   | 1.2 ± 0.4  | 0.621***|
| HDL                                | 46.6 ± 13.6| 43.4 ± 10.0   | 42.7 ± 13.4 | 45.0 ± 6.3  | 0.912***|
| LDL                                | 79.1 ± 27.1| 84.0 ± 21.5   | 75.9 ± 26.8 | 94.5 ± 11.6 | 0.206***|
| TG                                 | 168.3 ± 60.0| 186.7 ± 92.4 | 177.9 ± 126.7| 125.7 ± 55.0 | 0.450***|
| Chol                               | 161.8 ± 105.0| 160.9 ± 31.6 | 165.0 ± 79.3 | 164.2 ± 26.0 | 0.721***|
| VAR                                | 6.8 ± 3.4 | 6.8 ± 2.3     | 6.4 ± 2.5   | 3.2 ± 3.1  | 0.133***|
| VAL                                | 63.3 ± 3.3| 64.6 ± 2.6    | 63.7 ± 2.7  | 3.7 ± 2.9  | 0.285***|
| HTN                                | 9(64.3)   | 11(61.1)      | 6(50.0)     | 2(33.3)    | 0.364*  |
| Tyr (Hypothyroidism)               | 3(21.4)   | 4(22.2)       | 4(33.3)     | 1(16.7)    | 0.932*  |
| GI                                 | 9(64.3)   | 6(33.3)       | 9(75.0)     | 5(83.3)    | 0.026*  |
| ME                                 | 2(14.2)   | 3(16.7)       | 3(25.0)     | 2(33.3)    | 0.817*  |
| PR                                 | 2(14.2)   | 3(16.7)       | 2(16.7)     | 0(0.0)     | 0.840*  |
| Cat                                | 7(50.0)   | 11(61.1)      | 6(50.0)     | 3(50.0)    | 0.975*  |
| P                                  | 1(7.1)    | 8(44.4)       | 4(33.3)     | 0(0.0)     | 0.047*  |

Categorical and quantitative items have been shown by n (%) and Mean ± SD respectively SD: Standard Deviation

*Chi-square **ANOVA ***Kruskal–Wallis
variable that separates the patient with and without DR is HbA1C = 8.15, which leads in a sensitivity and specificity of 0.583 and 0.701, respectively (Table 4 and Fig 2). This high-specific cut-off point well identifies patients without retinopathy in the first stage of disease.

Discussion

The purpose of the present study was to determine whether the level of HbA1C can predict DR among T2DM. In our study, the prevalence of DR among T2DM patients was 29.8%. This was nearly similar to the study conducted in one of the north provinces in Iran. In this study, the prevalence of DR among diabetic patients was 23.8% [23]. In Iran's other meta-analysis the overall prevalence of DR among T2DM was 37.8% [3]. Also, the prevalence of DR was 33.5% in the Chinese population [24]. While, it was 18.58% in another study in China [25]. However, the prevalence of DR was higher among Saudi Arabia’s population. This study revealed the prevalence of DR was 40.0% [26].

In this cross-sectional study, ROC curve analysis and decision tree showed the appropriate cutoff point for detecting DR was HbA1C equal to 8.15. This value is similar to Aziz et al. study. He explored the cutoff point of 8.9% for developing DR with 67% sensitivity and 50% specificity. But this value was lower in other studies [26]. A study demonstrated that the optimal HbA1C threshold for detecting DR was 6.6% [19]. Iranian population-based study showed that optimal cut-off point of HbA1C was 6.2% [27]. In the previous study, one of the reasons for limited comparison was the discrepancy in participants. They assessed all diabetic and non-diabetic patients and people at least 40 years old. Based on the results of other studies, diversity in the optimal level of HbA1C for detecting DR might be due to taking an anti-hyperglycemic medication. An Egyptian study demonstrated that cut-off point level of HbA1C is higher among diabetic patients than non-diabetic people. It was 6.9% of the population, but after excluding consumers of anti-hyperglycemic medication the value changed to 7.5% [28]. This finding also had been seen in Xin et al. study. They showed the appropriate cut off point in the general population was 6.4%, but after modifying anti-hyperglycemic medication, consumers this value reached 6.7% [29].
Other reason that justify these difference is the possible effects of inadequate vitamin D. Long et al. reported that insufficient vitamin D might increase the risk of severe DR even in patients with well-controlled glycemia [30]. This possibility was missed in mentioned studies.

The limitation of the present study was the use of the population of one region, which limited the generalization of finding. Therefore, we suggest assessing more variables that may affect the relationship between DR and the level of HbA1c for future studies in this regard. One of the important risk factors is anemia. The literature review showed anemia may lead to diabetic retinopathy without renal disease [31, 32]. So, it is recommended to assess this variable in the future studies.

**Conclusion**

This cross-sectional study showed the prevalence of DR was 29.8% among T2DM patients. Also, the appropriate cut off point of HbA1C for detecting DR as a disabling complication is 8.15 among Iranian diabetic population. However, additional studies that modify confounding variables are needed to confirm the appropriate level of HbA1C for detecting the development of DR among diabetic patients.

**Acknowledgements**

This study was supported by research committee of Islamic Azad University, Sari branch. We thank Dr. Farhad Mashayekh Bakhshi, fellowship of endocrinology and metabolism, and all the diabetic patients for their honest cooperation in the study.

**Table 4 Cut-off point for HbA1C variable**

| Positive if Greater Than or Equal To | Sensitivity  | 1 - Specificity |
|-------------------------------------|--------------|-----------------|
| 5.45                                | 1.000        | 0.957           |
| 5.95                                | 0.979        | 0.923           |
| 6.45                                | 0.958        | 0.821           |
| 6.95                                | 0.854        | 0.709           |
| 7.35                                | 0.750        | 0.573           |
| 7.85                                | 0.646        | 0.410           |
| 8.05                                | 0.604        | 0.325           |
| 8.15                                | 0.583        | 0.299           |
| 8.35                                | 0.500        | 0.274           |
| 8.85                                | 0.313        | 0.231           |
| 9.25                                | 0.271        | 0.171           |
| 9.95                                | 0.167        | 0.094           |
| 10.75                               | 0.063        | 0.060           |
| 11.85                               | 0.000        | 0.034           |
| 12.25                               | 0.000        | 0.017           |
Authors' contributions
JS: Conceptualization, Methodology. AM: Supervision. BK: Analyzed data. GH, AE, AF, MZ, and MM: Visualization, Investigation, Writing- Original draft preparation. MK: Writing- Reviewing and Editing. MG: Reviewing and revising. All authors had final approval of the submitted and published versions.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the ethics committee of the Islamic Azad University, Sari branch (Ethical code: IR.IAU.SARI.REC.1399.009) and written informed consent was obtained from all participants. All methods were carried out in accordance with relevant guidelines and regulations. Also, Patients were reassured about the confidentiality of information.

Consent for publication
Not applicable.

Competing interests
The authors declare they have no conflict of interest.

Author details
1 Psychiatry and Behavioral Sciences Research Center, Addiction Institute, Mazandaran University of Medical Sciences, Sari, Iran. 2 Faculty of Medicine, Sari branch, Islamic Azad University, Sari, Iran. 3 Iran Helal Institute of Applied Science and Technology, Tehran, Iran. 4 Research Center for Health Management in Mass Gathering, Red Crescent Society of the Islamic Republic of Iran, Tehran, Iran. 5 Pediatric Infectious Diseases Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran. 6 Department of ophthalmology, Faculty of medicine, Sari branch, Islamic Azad University, Sari, Iran.

Received: 11 May 2022   Accepted: 16 September 2022
Published online: 31 October 2022

References
1. Zhou B, Lu V, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4–4 million participants. Lancet. 2016;387(10027):1513–30.
2. Federation. ID. IDF Diabetes Atlas. 2015. Available from: http://www.diabetesatlas.org/.
3. Mohammadi M, Raiegi AN, Jalali R, Ghobadi A, Salari N. The prevalence of retinopathy among type 2 diabetic patients in Iran: a systematic review and meta-analysis. Rev Endocrine Metab Disord. 2019;20(2):79–88.
4. WHO. Diabetes country profiles 2016. Available from: http://www.who.int/diabetes/profiles/en/.
5. Litwak L, Goh S-Y, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational a 1 chieve study. Diabetol Metab Syndr. 2013;5(1):57.
6. Wang W, Lo AC. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(46):1816.
7. Romero-Aroca P, Baget-Bernaldez M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Vergeres R. Diabetic macular edema pathophysiology- vaso-protean versus inflammatory. J Diabetes Res. 2016;2016. Article ID 2156273. https://doi.org/10.1155/2016/2156273.
8. Wykoff CC, Khurana RN, Nguyen QD, Kelly SP, Lum F, Hall R, et al. Risk of blindness among patients with diabetes and newly diagnosed diabetic retinopathy. Diabetes Care. 2021;44(3):748–56.
9. Lechner J, O'Leary OE, Stitt AW. The pathology associated with diabetic retinopathy. Vis Res. 2017;139:7–14.
10. Whitehead M, Wickremasinghe S, Osborne A, Van Wijngaarden P, Martin KR. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies. Expert Opin Biol Ther. 2018;18(12):1257–70.
11. Maroufzadeh S, Almasi-Hashani A, Hosseini M, Sepidarkish M, Samani RO. Prevalence of diabetic retinopathy in Iran: a systematic review and Meta-analysis. Int J Ophthalmol. 2017;10(5):782.
12. Chua J, Lim CXY, Wong TY, Sabanayagam C. Diabetic retinopathy in the Asia-Pacific. Asia Pacific J Ophthalmol. 2018;7(1):3–16.
13. Beagley J, Guariguata L, Weil C, Motaia AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2014;103(2):150–60.
14. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88.
15. Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, et al. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012;379(9833):2252–61.
16. (WHO) WHO. Diabetes. Available from: https://www.who.int/health-topics/diabetes#tab=3.
17. Matsushita Y, Takeda N, Nakamura Y, Yoshida-Hata N, Yamamoto S, Noda M, et al. A comparison of the Association of Fasting Plasma Glucose and HbA1c levels with diabetic retinopathy in Japanese men. J Diabetes Res. 2020;2020. Article ID 3214676. https://doi.org/10.1155/2020/3214676.
18. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia. 2009;52(1):17–30.
19. Cho NH, Kim TH, Woo SJ, Park KH, Lim S, Cho YM, et al. Optimal HbA1c cutoff for detecting diabetic retinopathy. Acta Diabetol. 2013;50(6):837–42.
20. Sumner AE, Thoresen CK, O'Connor MY, Ricks M, Chung ST, Tulloch-Reid MK, et al. Detection of abnormal glucose tolerance in Africans is improved by combining A1C with fasting glucose: the Africans in America study. Diabetes Care. 2015;38(2):213–9.
21. Yao L, Zhong Y, He L, Wang Y, Wu J, Geng J, et al. Serum CA125 level is associated with diabetic retinopathy in Chinese patients with type 2 diabetes. Diabetes Metab Syndrome Obes. 2020;13:1803.
22. Hamedia S, Yamashita H. International clinical diabetic retinopathy disease severity scale. Nihon Rinsho. Japan J Clin Med. 2010;68:228–35.
23. Katbebi M, Behboudi H, Moradian S, Alizadeh Y, Beiranvand R, Sababghi H, et al. Rapid assessment of avoidable blindness and diabetic retinopathy in Gilan province, Iran. Ophthalmol Epidemol. 2017;24(6):381–7.
24. Sun Q, Jing Y, Zhang B, Gu T, Meng R, Sun J, et al. The risk factors for diabetic retinopathy in a Chinese population: a cross-Sectional study. J Diabetes Res. 2021;2021. Article ID 5340453. https://doi.org/10.1155/2021/5340453.
25. Peng Y, Guo X, Liu J, Yao Y, Guo H, Wang Y, et al. Incidence and risk factors for diabetic retinopathy in the communities of Shenzhen. Ann Palliative Med. 2021;10(1):615–24.
26. Aziz KM. Association of Diabetic Retinopathy and Maculopathy with Elevated HbA1c. Blood Pressure, Serum Creatinine, Microalbuminuria, Spot Urine Protein, Nephropathy and Diabetic Kidney Disease An Experience from Data Analysis of. 2018;5(1):1–11.
27. Aidenloo NS, Meh dizadeh A, Valizadeh N, Abbasszadeh M, Qareeqan S, Khalkhali H. Optimal glycemic and hemoglobin A1c thresholds for diagnosing diabetes based on prevalence of retinopathy in an Iranian population. Iran Red Crescent Med J. 2016;18(9):e31254.
28. Engelgau MM, Thompson TJ, Hemami WH, Boyle JP, Aubert RE, Kenny SJ, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care. 1997;20(5):785–91.
29. Xin Z, Yuan M-X, Li H-X, Hua L, Feng J-P, Shi J, et al. Evaluation for fasting and 2-hour glucose and HbA1c for diagnosing diabetes based on prevalence of retinopathy in a Chinese population. PLoS One. 2012;7(7):e40610.
30. Long M, Wang C, Liu D. Glycated hemoglobin A1c and vitamin D and their association with diabetic retinopathy severity. Nutr Diabetes. 2017;7(6):e281-e.
31. Traveset A, Rubinat E, Ortega E, Alcubierre N, Vazquez B, Hernández M, et al. Lower hemoglobin concentration is associated with retinal ischemia and the severity of diabetic retinopathy in type 2 diabetes. J Diabetes Res. 2016;2016:3674946.

32. Scanlon PH. Improving the screening of risk factors in diabetic retinopathy. Expert Rev Endocrinol Metab. 2022;17(3):235–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.